Author's response to reviews

Title: Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study

Authors:

Philip B Miner Jr (Philip-Miner@ofdr.com)
Debra G Silberg (dsilberg@shire.com)
Magnus Ruth (magnus.ruth@live.se)
Frank Miller (mail@frank-miller.eu)
John Pandolfino (j-pandolfino@northwestern.edu)

Version: 3
Date: 23 May 2014

Author's response to reviews: see over
Dr Christopher Foote, Executive Editor, 
*BMC Gastroenterology*

Dear Dr Foote,

Please find enclosed a revised version of our manuscript entitled ‘Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study’ to be considered for publication in *BMC Gastroenterology*. We have responded to the comments from the editors and reviewers ( appended to the end of this cover letter), and have highlighted in yellow the corresponding changes to the text in the manuscript, as well as making some updates to the corresponding author address details and conflicts of interests section (in track-changes).

This manuscript reports original work, and is not under consideration for publication elsewhere. We appreciate the opportunity to submit a revised version of this work for your consideration, and look forward to hearing from you.

Yours sincerely,

Philip B. Miner Jr, MD (on behalf of colleagues)
Response to reviewers

Editorial comment 1:
Please include the full name of the ethics committee that approved your study in the Methods section of your manuscript. This information has been added to the manuscript on page 7.

Editorial comment 2: Please revise your 'author contributions' sections to specify the contribution of each individual author. The ‘author contributions’ have been revised as requested (page 20).

Reviewer comment 1: The paper is interesting and well conducted. The authors' reply to the Editor comments were satisfactory answered, though there is a point which deserves minor essential revision: "Proton pump inhibitors (PPI) partial responders" are mentioned in the manuscript. Although the differences among PPIs are small under the clinical aspect, it would be advisable to mention which PPI were used as well as their dosage. This information has been added to the manuscript on page 12.